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Abstract
Chronic kidney disease (CKD) is an increasing global public health concern, particularly among populations of African
ancestry. We performed an interrogation of known renal loci, genome-wide association (GWA), and IBC candidate-gene SNP
association analyses in African Americans from the CARe Renal Consortium. In up to 8,110 participants, we performed meta-
analyses of GWA and IBC array data for estimated glomerular filtration rate (eGFR), CKD (eGFR ,60 mL/min/1.73 m
2),
urinary albumin-to-creatinine ratio (UACR), and microalbuminuria (UACR .30 mg/g) and interrogated the 250 kb flanking
region around 24 SNPs previously identified in European Ancestry renal GWAS analyses. Findings were replicated in up to
4,358 African Americans. To assess function, individually identified genes were knocked down in zebrafish embryos by
morpholino antisense oligonucleotides. Expression of kidney-specific genes was assessed by in situ hybridization, and
glomerular filtration was evaluated by dextran clearance. Overall, 23 of 24 previously identified SNPs had direction-
consistent associations with eGFR in African Americans, 2 of which achieved nominal significance (UMOD, PIP5K1B).
Interrogation of the flanking regions uncovered 24 new index SNPs in African Americans, 12 of which were replicated
(UMOD, ANXA9, GCKR, TFDP2, DAB2, VEGFA, ATXN2, GATM, SLC22A2, TMEM60, SLC6A13, and BCAS3). In addition, we identified
3 suggestive loci at DOK6 (p-value=5.3610
27) and FNDC1 (p-value=3.0610
27) for UACR, and KCNQ1 with eGFR
(p=3.6610
26). Morpholino knockdown of kcnq1 in the zebrafish resulted in abnormal kidney development and filtration
capacity. We identified several SNPs in association with eGFR in African Ancestry individuals, as well as 3 suggestive loci for
UACR and eGFR. Functional genetic studies support a role for kcnq1 in glomerular development in zebrafish.
PLoS Genetics | www.plosgenetics.org 1 September 2011 | Volume 7 | Issue 9 | e1002264Citation: Liu C-T, Garnaas MK, Tin A, Kottgen A, Franceschini N, et al. (2011) Genetic Association for Renal Traits among Participants of African Ancestry Reveals
New Loci for Renal Function. PLoS Genet 7(9): e1002264. doi:10.1371/journal.pgen.1002264
Editor: Donna K. Arnett, University of Alabama, Birmingham, United States of America
Received January 31, 2011; Accepted July 5, 2011; Published September 8, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The following nine parent studies have contributed parent study data, ancillary study data, and DNA samples through the Massachusetts Institute of
Technology – Broad Institute (N01-HC-65226) to create this genotype/phenotype data base for wide dissemination to the biomedical research community:
Atherosclerotic Risk in Communities (ARIC): University of North Carolina at Chapel Hill (N01-HC-55015), Baylor Medical College (N01-HC-55016), University of
Mississippi Medical Center (N01-HC-55021), University of Minnesota (N01-HC-55019), Johns Hopkins University (N01-HC-55020), University of Texas Houston (N01-
HC-55022), University of North Carolina Forsyth County (N01-HC-55018); Cardiovascular Health Study (CHS): University of Washington (N01-HC-85079), Wake
Forest University (N01-HC-85080), Johns Hopkins University (N01-HC-85081), University of Pittsburgh (N01-HC-85082), University of California Davis (N01-HC-
85083), University of California Irvine (N01-HC-85084), New England Medical Center (N01-HC-85085), University of Vermont (N01-HC-85086), Georgetown
University (N01-HC-35129), Johns Hopkins University (N01 HC-15103), University of Wisconsin (N01-HC-75150), Geisinger Clinic (N01-HC-45133), University of
Washington (N01 HC-55222, U01 HL080295); Cleveland Family Study (CFS): Case Western Reserve University (NIH HL 46380, M01RR00080); Cooperative Study of
Sickle Cell Disease (CSSCD): University of Illinois (N01-HB-72982, N01-HB-97062), Howard University (N01-HB-72991, N01-HB-97061), University of Miami (N01-HB-
72992, N01-HB-97064), Duke University (N01-HB-72993), George Washington University (N01-HB-72994), University of Tennessee (N01-HB-72995, N01-HB-97070),
Yale University (N01-HB-72996, N01-HB-97072), Children’s Hospital-Philadelphia (N01-HB-72997, N01-HB-97056), University of Chicago (N01-HB-72998, N01-HB-
97053), Medical College of Georgia (N01-HB-73000, N01-HB-97060), Washington University (N01-HB-73001, N01-HB-97071), Jewish Hospital and Medical Center of
Brooklyn (N01-HB-73002), Trustees of Health and Hospitals of the City of Boston (N01-HB-73003), Children’s Hospital-Oakland (N01-HB-73004, N01-HB-97054),
University of Mississippi (N01-HB-73005), St. Luke’s Hospital-New York (N01-HB-73006), Alta Bates-Herrick Hospital (N01-HB-97051), Columbia University (N01-HB-
97058), St. Jude’s Children’s Research Hospital (N01-HB-97066), Research Foundation of the State University of New York-Albany (N01-HB-97068, N01-HB-97069),
New England Research Institute (N01-HB-97073), Interfaith Medical Center-Brooklyn (N01-HB-97085); Coronary Artery Risk in Young Adults (CARDIA): University of
Alabama at Birmingham (N01-HC-48047), University of Minnesota (N01-HC-48048), Northwestern University (N01-HC-48049), Kaiser Foundation Research Institute
(N01-HC-48050), University of Alabama at Birmingham (N01-HC-95095), Tufts-New England Medical Center (N01-HC-45204), Wake Forest University (N01-HC-
45205), Harbor-UCLA Research and Education Institute (N01-HC-05187), University of California Irvine (N01-HC-45134, N01-HC-95100); Framingham Heart Study
(FHS): Boston University (N01-HC-25195, R01HL092577-01A1, RO1 HL076784, R01 AG028321); Jackson Heart Study (JHS): Jackson State University (N01-HC-95170),
University of Mississippi (N01-HC-95171), Tougaloo College (N01-HC-95172); Multi-Ethnic Study of Atherosclerosis (MESA): University of Washington (N01-HC-
95159), Regents of the University of California (N01-HC-95160), Columbia University (N01-HC-95161), Johns Hopkins University (N01-HC-95162, N01-HC-95168),
University of Minnesota (N01-HC-95163), Northwestern University (N01-HC-95164), Wake Forest University (N01-HC-95165), University of Vermont (N01-HC-
95166), New England Medical Center (N01-HC-95167), Harbor-UCLA Research and Education Institute (N01-HC-95169), Cedars-Sinai Medical Center (R01-HL-
071205), University of Virginia (subcontract to R01-HL-071205); Sleep Heart Health Study (SHHS): Johns Hopkins University (U01 HL064360), Case Western
University (U01 HL063463), University of California, Davis (U01 HL053916), University of Arizona (U01 HL053938), University of Minnesota (relocating in 2006 to
Univ Arizona) (U01 HL053934), University of Pittsburgh (U01 HL077813), Boston University (U01 HL053941), MedStar Research Institute (U01 HL063429), Johns
Hopkins University (U01 HL053937). GENOA: The GENOA Study genome-wide association study was funded by NHLBI R01-HL087660. HABC: This research was
supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to
Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a
federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This research was supported in
part by the Intramural Research Program of the NIH, National Institute on Aging. Howard University Family Study: The Howard University Family Study was
supported by National Institutes of Health grants S06GM008016-320107 and S06GM008016-380111. Enrollment was carried out at the Howard University General
Clinical Research Center, supported by National Institutes of Health grant 2M01RR010284. This research was supported in part by the Intramural Research
Program of the Center for Research on Genomics and Global Health. The Center for Research on Genomics and Global Health is supported by the National Human
Genome Research Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the Center for Information Technology, and the Office of the
Director at the National Institutes of Health (Z01HG200362). Genotyping support was provided by the Coriell Institute for Medical Research. We thank the
participants of the Howard University Family Study. The contents of this publication are solely the responsibility of the authors and do not necessarily represent
the official view of the National Institutes of Health. HANDLS: This research was supported by the Intramural Research Program of the NIH, National Institute on
Aging and the National Center on Minority Health and Health Disparities (Intramural Project # Z01-AG000513 and human subjects protocol # 2009-149). Data
analyses for the HANDLS study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda,
MD. (http://biowulf.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: foxca@nhlbi.nih.gov (CSF); wkao@jhsph.edu (WLK); wgoessling@partners.org (WG)
. These authors contributed equally to this work.
" These authors were joint senior authors on this work.
Introduction
Chronic kidney disease (CKD) affects approximately 15% of U.S
adults[1].Dueinparttoincreasingratesofdiabetesandobesity,the
prevalence of CKD continues to rise [1]. Marked variability in the
incidence of CKD suggests that factors other than diabetes and
hypertension contribute to its etiology [2]. Recently, we identified
16 genomic loci associated with estimated glomerular filtration rate
(eGFR), a primary measure of CKD, using genome-wide
association studies (GWAS) in a combined sample of 67,093
European ancestryindividualsfromtheCKDGenconsortium[3,4].
However, these loci only account for 1.4% of the eGFR variation,
suggesting that additional loci remain to be identified [5].
African American ethnicity is a well-established risk factor for
CKD, and rates of end-stage renal disease (ESRD) are up to 4-
fold higher among African Americans as compared to European
Americans [6]. Several prior studies, including the FIND
consortium, have performed linkage analysis of diabetic ESRD
[7–9]. Recent genome-wide admixture mapping studies identi-
fied genetic variation in the regions of MYH9 and APOL1 on
chromosome 22 that may explain up to 70% of the differences in
ESRD rates between European and African Americans [10–12].
While this finding has great implications for ESRD, recent
evidence also suggests that African Americans progress faster
from moderately decreased kidney function to ESRD, spending
less time in the recognized earlier stages of CKD [13,14]. The
identification of additional risk factors for CKD, including
genetic loci in association with eGFR, may help to advance our
understanding of the underpinnings of CKD in African
Americans.
Thus, the goal of this study was to uncover loci for kidney traits in
African ancestry participants in the Candidate-gene Association
Resource (CARe) Consortium. CARe is a consortium of 9 studies
which form a combined population of approximately 40,000
African and European Americans genotyped on the IBC array [15]
and approximately 8,000 African American participants genotyped
Renal Genetics in African Americans
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previously associated with eGFR in European Ancestry populations
[3,4], as well as to perform discovery analyses in African ancestry
populations. In order to gain further insight into the functional
implications of our associations, genes at or near loci ofinterest were
knocked down by morpholino injection in zebrafish, and kidney
gene expression and function were investigated using in situ
hybridization and glomerular filtration assays.
Results
Study sample characteristics are shown in Table 1 and Table
S1. Overall, 7,382 participants of African ancestry had genome-
wide SNP data and phenotype information on eGFR and CKD;
and 5,569 had data on UACR and albuminuria. For the IBC chip
analysis, 8,110 participants of African ancestry had data on eGFR
and CKD and 5,995 had data on UACR and albuminuria.
Interrogation of Known Renal Function Loci in African
American Participants
Genome-wide association analyses were conducted for eGFR,
CKD, UACR, and albuminuria. Quantile-quantile and Manhat-
tan plots are displayed in Figure S1 and Figure S2, respectively;
lambdas ranged from 1.0 to 1.02.
We examined previously published loci in association with
eGFR in participants of European Ancestry [3,4,16] in our
African American GWAS (Table 2). In 23 of 24 SNPs, the
directions of the beta coefficients for eGFR were identical
(p-value=1.4*10
26) in CKDGen and CARe (rs6420094 at
SLC34A1 was the only exception), even though only 2 of the
SNPs achieved nominal significance (rs4293393 at the UMOD
locus [p=0.01] and rs4744712 at the PIP5K1B locus [p=0.003]).
We further interrogated the 250 kb flanking regions around each
of these 24 SNP to identify the top SNP in CARe; statistical
Table 1. Study sample characteristics in the CARE Renal Consortium.*
Study
Sample Size
eGFRcrea/UACR
European
Ancestry1 % Women %
Age
(years)
eGFRcrea
(ml/min/1.73 m
2) UACR (mg/g)1 MA (%) CKD %
CARE African Ancestry Stage 1 Participants
ARIC 2786/1936 15.3(10.7,22.1) 63.1 53.3 99.9 2.69(0.85,9.94) 16.5 3.7
CARDIA 821/754 16.7(12.2,23.2) 61.1 39.4 111 4.28(3.09,7.40) 9.4 0.9
CHS** 728/426 20.6(12.4,32.7) 62.8 72.9 81.4 10.95(5.00,26.90) 31.9 18.4
JHS 2135/1246 15.7(11.8,21.1) 60.8 50 101 6.00(4.00,12.00) 16.5 4.2
MESA 1640/1633 18.8(11.5,29.7) 54.8 62.2 86.5 5.50(3.10, 13.10) 16.4 8.6
Total 8110/5995
CARE European Ancestry
ARIC 9581/7687 NA 53.5 54.3 90.3 3.94(2.04,7.69) 9.3 3.5
CARDIA 1331/1242 NA 53.2 40.7 99.2 4.42(3.30,6.90) 4.5 0.5
CHS 3938/2073 NA 56.1 72.8 76.4 10.20(5.50,22.70) 26.4 21
FHS 6624/6208 NA 53.6 48.8 94 4.50(2.60,9.57) 9.1 3.9
MESA 2293/2287 NA 52.3 62.7 82.4 4.70(3.10,8.60) 9.5 9.7
Total 23767/19497
Stage 2: Replication
GENOA 1217/1228 12.6(7.2,18.9) 71.7 63.2 88 6.13 (2.97, 19.73) 22.9 13
HANDLS 989/629 16.1(11.2,22.0) 55 48.4 121 5.26(3.17,15.96) 20.3 5.3
Health ABC 1139/253 22.4 (12.2, 32.6) 57.2 73.4 76.3 19.3(5.7, 96.5) 47 17.1
HUFS 1013/NA 19.7(14.3,27.0) 58.8 48.3 104.3 NA NA 4.9
Total 4358/2110
Abbreviations: eGFRcrea: estimated glomerular filtration rate by serum creatinine, eGFRcys: estimated glomerular filtration rate by serum cystatin C, CKD: chronic kidney
disease, HTN: hypertension, DM: diabetes mellitus, NA: not available.
* Sample characteristics based on the larger eGFR sample.
** CHS only has data on the IBC platform.
1 Median, 25/75
th percentile.
doi:10.1371/journal.pgen.1002264.t001
Author Summary
Chronic kidney disease (CKD) is an increasing global public
health problem and disproportionately affects populations
of African ancestry. Many studies have shown that genetic
variants are associated with the development of CKD;
however, similar studies are lacking in African ancestry
populations. The CARe consortium consists of more than
8,000 individuals of African ancestry; genome-wide asso-
ciation analysis for renal-related phenotypes was conduct-
ed. In cross-ethnicity analyses, we found that 23 of 24
previously identified SNPs in European ancestry popula-
tions have the same effect direction in our samples of
African ancestry. We also identified 3 suggestive genetic
variants associated with measurement of kidney function.
We then tested these genes in zebrafish knockdown
models and demonstrated that kcnq1 is involved in kidney
development in zebrafish. These results highlight the
similarity of genetic variants across ethnicities and show
that cross-species modeling in zebrafish is feasible for
genes associated with chronic human disease.
Renal Genetics in African Americans
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correction (see statistical methods for more detail). Of the 24 SNPs
with the lowest p-value in each of these regions identified in CARe
African Americans, we were able to replicate 12 loci (UMOD,
ANXA9, GCKR, TFDP2, DAB2, VEGFA, ATXN2, GATM,
SLC22A2, TMEM60, SLC6A13, and BCAS3) in independent
samples of 4358 participants (Table 3, Figure S3).
We also interrogated the CARe CKD GWAS results at the
chromosome 22 MYH9/APOL1 locus (Figure S4); however, none
of the G1 haplotype SNPs in APOL1 was present in our GWAS
dataset. The lowest p-value was observed for rs739097 (MAF 0.36,
p=0.00179), which was in weak LD with the previously described
rs4821480 in MYH9 (r2 0.03, D9 0.38 as determined by Hapmap
Release 22 YRI phase 2) [10].
Genome-Wide Association Analyses for Renal Indices
We performed discovery analyses using GWAS and the IBC
chip array; p-value thresholds for discovery were p,5.0*10
28 for
GWAS and p,2.0*10
26 for the IBC array [17]. We observed no
genome-wide signals; instead, we carried forward 8 SNPs from
GWAS that had a p-value,5*10
26 in Stage 1 for replication;
results for these SNPs are presented in Table 4.
Replication was performed in 4,358 participants of African
ancestry for eGFR and 2,110 for UACR. Characteristics of the
replication samples are shown in Table 1. Results from discovery,
replication, and the combined GWAS analyses in African
Americans are presented in Table 4 (imputation scores can be
found in Table S2). Of the 8 SNPs from GWAS carried forward to
replication, the combined Stage 1 + Stage 2 p-value was 5.3*10
27
for the association between UACR and rs4555246 in DOK6
(Figure 1a) and the combined p-value was 2.9*10
27 for association
between UACR and rs2880072 in FNDC1 (Figure 1b). Due to
modest power of our replication set and the possibility that loci
relevant for CKD may be similar across ethnic groups, we also
attempted replication of the association between UACR and these
two loci in the CKDGen consortium, a large consortium of
participants of European ancestry (n=31,580 with UACR [18]).
The beta coefficient for rs4555246 in DOK6 in the CKDGen data
was direction-consistent, although the p-value for this SNP was
non-significant (p=0.44). Recognizing that regions, but not
necessarily specific tagging SNPs, may replicate across ethnicities,
we interrogated the 250 kb flanking region of rs4555246 (n=31
independent SNPs). The SNP with the lowest p-value was
rs11151530 (MAF 0.17, p=0.008), which did not meet the
Table 2. Interrogation of known loci in EA in AA for the trait eGFRcrea; best SNP at each locus is shown below; SNP ID in bold from
Kottgen et al, Nature Genetics 2009, and Nature Genetics 2010.
SNP ID in EA Chr
Genes Within
60 kb
Coded Allele
Frequency
(allele)
Beta coefficient
in EA relative
to coded allele
Coded allele
frequency for
the lead SNPs
in EA in
AA (allele)
Beta coefficient
in AA for the
lead SNP
in EA
p-value in
AA for lead
SNP in EA
rs17319721 4 SHROOM3 0.43 (A) 20.013 0.22 (A) 20.004 0.44
rs10109414 8 STC1 0.42 (T) 20.008 0.34 (T) 20.005 0.30
rs4293393* 16 UMOD 0.82 (A) 20.016 0.81 (A) 20.013 0.01
rs267734 1 ANXA9 0.8 (T) 20.010 0.96 (T) 20.016 0.13
rs1260326 2 GCKR 0.41 (T) 0.009 0.16 (T) 0.007 0.24
rs13538 2 ALMS1 0.77 (A) 20.009 0.48 (A) 20.003 0.57
rs347685 3 TFDP2 0.72 (A) 20.009 0.75 (A) 20.007 0.13
rs11959928 5 DAB2 0.44 (A) 20.009 0.30 (A) 20.002 0.75
rs6420094 5 SLC34A1 0.66 (A) 0.011 0.83 (A) 20.002 0.83
rs881858 6 VEGFA 0.72 (A) 20.011 0.36 (A) 20.003 0.50
rs10224210 7 PRKAG2 0.73 (T) 0.010 0.92 (T) 0.019 0.06
rs4744712 9 PIP5K1B 0.39 (A) 20.008 0.42 (A) 20.015 0.0003
rs653178 12 ATXN2 0.51 (T) 0.003 0.92 (T) 0.001 0.87
rs626277 13 DACH1 0.60 (A) 20.009 0.34 (A) 20.003 0.50
rs1394125 15 UBE2Q2 0.35 (A) 20.009 0.35 (A) 20.007 0.15
rs12460876 19 SLC7A9 0.61 (T) 20.008 0.72 (T) 20.010 0.03
rs10794720 10 WDR37 0.08 (T) 20.014 0.21 (T) 20.007 0.18
rs491567 15 WDR72 0.78 (A) 20.009 0.45 (A) 20.001 0.87
rs2453533 15 SPATA5L1;GATM 0.38 (A) 20.013 0.84 (A) 20.008 0.18
rs7422339 2 CPS1 0.32 (A) 20.009 0.32 (A) 20.005 0.38
rs2279463** 6 SLC22A2 0.88 (A) 0.013 N/A N/A N/A
rs6465825 7 TMEM60 0.61 (T) 0.008 0.51 (T) 0.000 0.92
rs10774021 12 SLC6A13 0.64 (T) 20.008 0.50 (T) 20.005 0.23
rs9895661 17 BCAS3 0.81 (T) 0.011 0.53 (T) 0.008 0.05
* Lead SNP rs12917707 in EA not present in AA dataset; therefore used rs4293393, which is in perfect LD in EA (r2=1.0).
** rs2279463 not present in AA dataset.
doi:10.1371/journal.pgen.1002264.t002
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PLoS Genetics | www.plosgenetics.org 4 September 2011 | Volume 7 | Issue 9 | e1002264Table 3. Interrogation of known loci in EA in AA for the trait eGFRcrea; best SNP at each locus is shown below; SNP ID in bold from
Kottgen et al, Nature Genetics 2009, and Nature Genetics 2010.
SNP ID
in EA Chr
Best SNP
ID in AA in
the Region
Coded
Allele
Frequency
in AA
(allele)
Beta
coefficient
in AA for
best SNP
P-value
in AA
Number of
independent
(typed) SNPs
interrogated
in CARe AA
Bonferroni
p-value
threshhold
(0.05/P)
Replication
beta
coefficient
Replication
p-value
Stage
1+Stage
2 beta
Stage
1+Stage 2
p-value
rs17319721 4 rs4371638 0.19 (T) 20.020 0.003 28 0.002 20.002 0.42 20.015 8.8E-03
rs10109414 8 rs192841 0.79 (A) 20.016 0.007 29 0.002 0.012 0.91 20.008 1.3E-01
rs4293393 16 rs4293393 0.81 (A) 20.013 0.014 14 0.004 20.017 0.02 20.014 1.5E-03
rs267734 1 rs3738479 0.39 (A) 0.013 0.005 19 0.003 0.012 0.04 0.013 9.0E-04
rs1260326 2 rs13022873 0.81 (A) 0.013 0.017 17 0.003 0.007 0.21 0.011 1.3E-02
rs13538 2 rs7600291 0.58 (C) 0.011 0.011 19 0.003 20.011 0.93 0.005 1.6E-01
rs347685 3 rs6781340 0.41 (T) 20.014 0.002 21 0.002 20.014 0.03 20.014 2.1E-04
rs11959928 5 rs3822460 0.83 (T) 20.013 0.020 11 0.005 20.010 0.13 20.012 1.0E-02
rs6420094 5 rs10463065 0.95 (C) 0.032 0.004 20 0.003 20.001 0.52 0.023 1.6E-02
rs881858 6 rs1750571 0.07 (A) 0.023 0.005 31 0.002 0.027 0.02 0.024 5.0E-04
rs10224210 7 rs6464167 0.42 (A) 0.015 0.021 20 0.003 0.004 0.33 0.010 3.5E-02
rs4744712 9 rs1556751 0.59 (A) 0.016 0.0002 65 0.001 0.006 0.19 0.013 2.6E-04
rs653178 12 rs12302645 0.94 (A) 20.018 0.050 10 0.005 20.014 0.16 20.017 3.0E-02
rs626277 13 rs9318029 0.13(T) 0.016 0.046 7 0.007 0.002 0.42 0.011 8.5E-02
rs1394125 15 rs2454472 0.84 (A) 20.020 0.0009 28 0.002 20.007 0.25 20.016 1.4E-03
rs12460876 19 rs3795058 0.43 (C) 20.012 0.004 30 0.002 0.009 0.88 20.007 6.7E-02
rs10794720 10 rs2805575 0.20 (C) 0.013 0.01 45 0.001 20.016 0.97 0.005 2.3E-01
rs491567 15 rs16966247 0.17 (C) 20.022 0.0002 35 0.001 20.004 0.31 20.017 6.0E-04
rs2453533 15 rs1153859 0.52 (T) 20.014 0.001 14 0.004 20.012 0.04 20.013 2.2E-04
rs7422339 2 rs957749 0.79 (A) 20.011 0.04 13 0.004 0.007 0.82 20.006 2.0E-01
rs2279463 6 rs3798156 0.12 (T) 20.027 7.8E-05 22 0.002 20.032 0.003 20.028 1.2E-06
rs6465825 7 rs6973213 0.20 (A) 20.019 2.79E-04 25 0.002 20.008 0.19 20.017 2.75E-04
rs10774021 12 rs485514 0.91 (T) 0.019 0.03 20 0.003 0.013 0.17 0.017 1.6E-02
rs9895661 17 rs11650989 0.22 (A) 0.016 0.002 20 0.003 0.013 0.06 0.016 5.8E-04
doi:10.1371/journal.pgen.1002264.t003
Table 4. Stage 1 and Stage 2 results from loci in African Americans from GWAS (p,5.0*10E-06): SNP association with renal traits.
Trait SNP ID Chr
Genes In
or Nearby
SNP
function
Coded Allele
Frequency# Beta
Stage 1
P-value
Replication
beta for
lead trait
Stage 2
p-value
Stage
1+Stage
2 beta
Stage
1+Stage
2 p-value
GWAS
UACR rs4555246 18 DOK6 Intron 0.77 (A) 0.156 8.74E-07 0.078 0.10 0.140 5.33E-07
UACR rs13213851 6 HACE1 N/A 0.68 (A) 20.130 1.86E-06 0.102 0.97 20.084 5.25E-04
UACR rs2880072 6 FNDC1 N/A 0.66 (A) 20.128 1.99E-06 20.097 0.04 20.122 2.98E-07
MA rs1009840 6 SGK1 Intron 0.19 (A) 0.363 2.62E-07 0.034 0.36 0.246 1.21E-05
eGFRcrea rs6581768 12 DYRK2 N/A 0.87 (A) 0.035 3.00E-07 0.002 0.43 0.029 2.62E-06
eGFRcrea rs7784820 7 GNAT3 N/A 0.70 (A) 0.023 5.30E-07 20.008 0.87 0.014 2.33E-04
CKD rs12575381 11 B3GAT1 N/A 0.18 (A) 0.521 9.97E-07 20.127 0.90 0.179 1.26E-02
CKD rs6428106 1 RGS1 downstream 0.17(T) 0.549 2.95E-07 0.144 0.07 0.334 3.70E-06
IBC
eGFRcrea rs7111394 11 KCNQ1 Intron 0.83 (T) 20.025 4.67E-06 20.012 0.10 20.0213 3.61E-06
eGFRcys rs6865647 5 PDE4D Intron 0.74 (A) 0.108 1.491E-07 20.007 0.74 0.0169 6.87E-02
CKD rs4648006 4 NFKB1 Intron 0.13 (T) 0.433 1.06E-05 20.140 0.89 0.1886 1.07E-02
doi:10.1371/journal.pgen.1002264.t004
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doi:10.1371/journal.pgen.1002264.g001
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FNDC1, the beta coefficient for the lead SNP was direction-
consistent in CKDGen (beta=20.0196), although the p-value was
not significant (p=0.053). Interrogating the 250 kb flanking
region (n=7 independent SNPs) revealed that rs7758822 had
the lowest p-value at p=0.002 (MAF 0.12), which met the
Bonferroni-corrected threshold of p=0.007 (0.05/7).
IBC Chip Analyses for Renal Function Indices
In European Americans, we confirmed several known loci for
eGFR/CKD [3,4,16]; no novel genome-wide significant associa-
tions (defined as p,2.0*10
26) were identified (Table S3). In
African Americans, three loci for eGFR/CKD were brought
forward to replication (Table 4). Of these, we observed nominal
replication for rs7111394 in the KCNQ1 gene (Figure 2a, Stage 1 +
Stage 2 p-value=3.6*10
26). This SNP was not identified in the
European American analysis as it was monomorphic in this
population. Thus, we interrogated the 250 kb flanking region
around this SNP (93 independent SNPs) in the CARe IBC
European ancestry participants. The SNP with the lowest p-value
was rs81204 (Figure 2b, MAF 0.16, p-value=0.00036), which
exceeded the corrected regional-specific threshold of 0.000538
(0.05/93).
Functional Studies of New Loci for Renal Function
To further understand the impact of the three new loci on
kidney function and to bolster confidence in the sub-genome-wide
statistical associations that we observed, we performed morpholino
knockdown of kcnq1, dok6, and fndc1 in zebrafish embryos (see
methods).
In situ hybridization for well-established renal markers was used
to assess specific anatomic regions of the kidney during
development. Kcnq1 knockdown caused abnormalities in glomer-
ular gene expression in the majority of injected embryos, as shown
by the global kidney marker pax2a at 48 hours post fertilization
(hpf) (see Table 5, Figure 3F). Assessment of the podocyte markers
wt1a at 24 hpf and nephrin at 48 hpf revealed similar, glomerular-
specific effects. In contrast, the tubular markers slc20a1a and
slc12a3 showed no significant changes. Analysis of glomerular
architecture at 120 hpf by electron microscopy did not demon-
strate significant differences between control and kcnq1 morphant
embryos (Figure S5), possibly due to diminished morpholino
efficacy at this later stage. Knockdown of dok6 and fndc1 did not
result in generalized edema or significant developmental abnor-
malities of the kidney (Table 5, Figure S6).
To determine whether differences in gene expression resulted in
altered kidney function, we evaluated glomerular filtration in kcnq1
morphant embryos by assessing the kidney’s capacity to retain
fluorescent dextran. Fluorescently labeled high-molecular weight
dextran has been used in zebrafish to directly visualize functional
glomerular integrity [19]. Control or kcnq1 morphant embryos
were equally loaded with rhodamine-labeled 10,000 MW dextran
by injection into the cardiac sinus venosus at 48 hpf (Figure S7A,
S7D). Dextran clearance was assessed by overall fluorescence in
the embryo at 72 and 96 hpf (Figure S7B, S7C, S7E, S7F) and
presence of red fluorescence in the green fluorescent tubules of
cdh17:GFP reporter embryos. Kcnq1 morphant embryos exhibited
decreased fluorescence by 96 hpf, indicative of increased dextran
clearance compared to control embryos (Figure 4C, 4F). Time
course analysis confirmed equal loading and progressive loss of
fluorescence over 48 hours in kcnq1 morphants. These results
suggest that loss of kcnq1 causes decreased glomerular retention of
macromolecules. The majority of embryos with increased loss of
dextran fluorescence also exhibited generalized edema (Figure 4A,
4B, 4D, 4E, 4G), which has been previously linked to kidney
dysfunction in zebrafish [20,21].
Cross-Trait Associations
rs4555246 in DOK6 was associated with albuminuria (OR=1.20,
p=0.001) but not with eGFR (p=0.23) or CKD (p=0.92; Table
S4). Similarly, rs2880072 in FNDC1 was associated with albumin-
uria (OR=0.83, p=4.9*10
25) but not with eGFR or CKD.
Although rs7111394 in KCNQ1 was associated with eGFR, it was
not significantly associated with CKD (direction consistent OR
1.07, p=0.36), UACR, or albuminuria. These findings underscore
the specificity of the genetic underpinnings of eGFR as compared to
albuminuria.
Stratification by Hypertension and Diabetes Status
All replicating loci were stratified by hypertension and diabetes
status (Table S5). We observed nominal significance for nearly all
loci in the non-diabetes and non-hypertension strata, and many
loci retained statistical significance in the diseased strata despite
smaller sample sizes.
Discussion
In more than 8,000 African Americans, for 24 known renal
susceptibility loci identified in European ancestry consortia for
eGFR and CKD, we have identified the most significant SNP in
African Americans, of which several showed evidence of
confirmation or replication. In addition, we performed discovery
analyses using GWAS and a candidate-gene based array, and
uncovered 3 suggestive loci, including KCNQ1 in association with
eGFR and DOK6 and FNDC1 in association with UACR. Finally,
we show that loss of function of kcnq1 leads to abnormalities in
glomerular gene expression and function during zebrafish
development.
Despite having one of the largest GWAS datasets in African
Americans, both our discovery and replication samples were of
relatively modest size. Thus, we have focused primarily on
interrogating regions previously identified in well-powered Euro-
pean ancestry meta-analyses for renal function in order to reduce
our genome-wide penalty for multiple testing. While we have
uncovered 3 suggestive loci, the strength of the statistical
significance is only suggestive. Because of this, we have
corroborated our findings with functional data from zebrafish,
providing compelling evidence for the role of KCNQ1 in renal
abnormalities.
Several prior genome-wide studies using GWAS or admixture
approaches have identified loci for renal function in participants of
European [3,4,16] and African ancestry [10,11]. These studies
have identified loci for eGFR, CKD, and non-diabetic ESRD;
however, few novel discoveries and relatively limited replication
have been made for renal function indices in African Americans.
African ancestry populations have smaller LD blocks and hence
more genetic diversity, thus offering the potential opportunity to
fine map genomic regions and to identify novel genomic regions
for indices of renal function.
The genes located closest to our three suggestive loci are KCNQ1
in association with eGFR, as well as FNDC1 and DOK6 in
association with UACR. KCNQ1 on chromosome 11 encodes for
the potassium voltage-gated channel, KQT-like subfamily,
member 1 (KvLQT1). The lead SNP identified among the
African ancestry participants is located in an intron of KCNQ1 and
is flanked by two recombination hotspots. The kcnq1 protein is
abundantly expressed in the brush border membrane of renal
proximal tubule cells, where it interacts with other K
+ channels
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PLoS Genetics | www.plosgenetics.org 7 September 2011 | Volume 7 | Issue 9 | e1002264Figure 2. Regional association plots for KCNQ1. For A) KCNQ1 in participants of African ancestry and B) in participants of European ancestry.
doi:10.1371/journal.pgen.1002264.g002
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+ secretion. Loss of Kcnq1 in the mouse
leads to impaired Na+ absorption with increased glucose load,
however, developmental abnormalities have not been reported
[22]. Variants in KCNQ1 have been associated with type 2 diabetes
[23] and beta cell function [24], due to its role as a potassium
channel in the pancreatic beta cells. A recent study of individuals
Table 5. Number of observed abnormalities/number of embryos examined at 200 uM injection (kcnq1) and 400 uM injection
(dok6 and fndc1).
Global Renal
Marker pax2a
Podocyte
Marker wt1a
Podocyte
Marker nephrin
Proximal Tubular
Marker slc20a1a
Distal Tubular
Marker slc12a3
Control MO 2/49 (4.1%) 3/63 (4.8%) 2/47 (4.3%) 45/142 (31%) 0/62 (0%)
kcnq1
Splice 45/68 (66%) 30/60 (50%) 35/50 (70%) 54/143 (38%) 0/35 (0%)
ATG 46/68 (68%) 33/78 (42%) 29/46 (63%) 65/157 (41%) 0/41 (0%)
Chi-Sqr p-value* ,0.0001 ,0.0001 ,0.0001 0.34 1
Chi-Sqr p-value** ,0.0001 ,0.0001 ,0.0001 0.11 1
Uninjected control 0/38 (0%) 0/31 (0%) 0/60 (0%) 1/16 (6%) 0/18 (0%)
dok6
ATG 5/54 (9%) 3/28 (11%) 1/50 (2%) 5/32 (16%) 2/42 (5%)
Chi-Sqr p-value** 0.14 0.2 0.93 0.65 0.88
fndc1
Splice 4/39 (10%) 1/30 (3%) 0/51 (0%) 8/31 (26%) 0/35 (0%)
Chi-Sqr p-value* 0.13 0.99 1 0.22 1
*Control or Uninjected versus splice MO.
**Control or Uninjected versus ATG MO.
doi:10.1371/journal.pgen.1002264.t005
Figure 3. Kcnq1 knockdown in zebrafish embryos causes glomerular abnormalities. (A–E) Zebrafish embryos injected with control
morpholino show normal glomerular and tubular morphology, as shown by in situ hybridization for the global kidney marker pax2a (A, inset showing
lower-magnification image, with staining in both glomerulus and tubules), the podocyte markers wt1a (B) and nephrin (C), and the proximal and
distal tubular markers slc20a1a (D) and slc12a3 (E). (F–J) Injection of the kcnq1 antisense morpholino, targeting the ATG site of the gene, at the one-
cell stage results in significant changes in glomerular gene expression (F–H). No changes were observed in the proximal tubule (I) or the distal tubule
(J).
doi:10.1371/journal.pgen.1002264.g003
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association with diabetic nephropathy [25]. Our lead SNP is not in
LD with this signal in either European or African ancestry
individuals. Importantly, we observe a strong and significant
association with KCNQ1 among participants without diabetes, and
our functional work suggests an independent association of kcnq1
in renal development. Thus, it is unlikely that our observed
associations are solely due to the association of KCNQ1 with
diabetes.
The DOK6 gene on chromosome 18 encodes a member of a
family of intracellular adaptor proteins that have a role in the
assembly of multimolecular signaling complexes. It is expressed in
the human kidney as well as the ureteric buds of the murine
developing kidney [26]. Although a direct role in renal disease has
not been described so far, DOK6 interacts with Ret [26], the
ablation of which resulted in kidney agenesis in model systems
[27]. The lead SNP we identified is located in an intron of a very
circumscribed region of the gene. DOK6 has been recently found
in a GWAS for osteoporosis [28], although our lead SNP is not in
LD with this variant.
The fibronectin type III domain containing 1 (FNDC1) gene on
chromosome 6 is also expressed in the kidney; the lead SNP is
located nearly 100 kb downstream of the gene. Little is known
about the function of this gene to date; previous studies found that
FNDC1 may mediate G protein signaling and have a role in
hypoxia-induced apocytosis of cultured ventricular cardiomyocytes
[29,30].
Zebrafish have been extensively used to study principal
pathways of kidney development and function [31,32]. More
recently, adult models of kidney injury have been developed [33].
For example, targeted knockdown of a prolyl 4-hydroxylase
resulted in kidney dysfunction with edema and changes in
podocytes and Bowman’s capsule [34]. In addition, a zebrafish
model of human nephrotic syndrome was generated by plce1
knockdown after positional cloning of this gene in affected siblings,
similarly resulting in cardiac edema and functional abnormalities
[35]. Here, we use morpholino knockdown to demonstrate that
loss of kcnq1 leads to changes in global morphology and gene
expression abnormalities during zebrafish kidney development.
Furthermore, in vivo fluorescence-based functional analysis of
zebrafish glomerular filtration capacity demonstrated decreased
retention of macromolecules, as previously demonstrated for other
genes affecting glomerular integrity [19,20]. Interestingly, KCNQ1
was identified in association with eGFR, and knockdown of kcnq1
in zebrafish predominantly causes glomerular gene expression and
filtration defects. These results suggest that genes associated with
polygenic chronic conditions can produce developmental pheno-
types when knocked down in vivo.
Our analytic approach was complemented by a large-scale
candidate gene analysis using the IBC SNP Chip array [15] and
replication of our findings in an additional 4358 African American
individuals. By using participants from predominantly population-
based cohorts, we were able to study disease initiation. An
important focus of our multi-ethnic samples allowed us to explore
Figure 4. Tg(cdh17:GFP) embryos were injected with 200 uM control or kcnq1 morpholino (MO) at the 1-cell stage. Embryos were
subsequently injected in the sinus venosus with 10,000 MW rhodamine dextran at 48 hpf. Dextran clearance was monitored over the next 48 hours
by confocal microscopy. Compared to control MO-injected embryos (A–C), kcnq1 MO-injected embryos exhibit edema (D, E) and increased dextran
clearance (F) 48 hours post-injection (hpi), suggestive of a filtration defect. At 5 dpf, 87% of kcnq1 morphant embryos (n=38) develop edema (G).
doi:10.1371/journal.pgen.1002264.g004
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regions are observed across ethnicities. Our replication was
derived from in silico samples, which allowed for the adjustment
for principle components where necessary. Finally, we were able to
corroborate our results in the zebrafish, a model organism for
studying vertebrate kidney development.
While the advantage of the zebrafish model is to rapidly assess
gene function during development, the role of genes in aging and
chronic disease cannot be modeled by transient morpholino
knockdown. eGFR was estimated using the MDRD study
equation, as obtaining gold-standard measures of GFR in large
population-based samples is not feasible. Serum creatinine and
albuminuria were measured at a single-point in time, which may
misclassify certain individuals and bias our results toward the null.
Even with imputation, the coverage of the genome in African
Americans is not comprehensive, thus limiting our statistical
power. With respect to the chromosome 22 MYH9/APOL1 locus,
neither the E1 haplotype in MYH9 nor the G1 haplotype in
APOL1 were in our GWAS dataset, limiting our ability to examine
this region in association with more modest CKD phenotypes.
Finally, our power was low for CKD to detect SNPs with odds
ratios of 1.2, the largest odds ratio detected in other GWAS for
CKD [4].
We identified several SNPs in association with eGFR in African
Ancestry individuals, as well as 3 suggestive loci for UACR and
eGFR. Functional genomic studies support a role for kcnq1 in
glomerular development and function in zebrafish.
Methods
Renal Function Indices
Serum creatinine was measured as described in Text S1. Serum
creatinine was calibrated to NHANES in all studies (including
replication cohorts) to account for between-laboratory variation as
previously described [3,36,37]. Glomerular filtration rate was
calculated based on serum creatinine (eGFR) with the Modification
of Diet in Renal Disease (MDRD) equation [38]. We defined
chronic kidney disease (CKD) as eGFR ,60 ml/min/1.73 m
2 in
accordance with the National Kidney Foundation guidelines; CKD
was based on a single serum creatininemeasurement as described in
Text S1. Urinary albumin to creatinine ratio (UACR, mg/g) was
computedasdescribedinTextS1;microalbuminuriawasdefinedas
UACR .17 mg/g [men] and .25 mg/g [women].
Covariate Definitions
We defined diabetes as fasting glucose $126 mg/dl, self-report,
or pharmacologic treatment. Similarly, hypertension was defined
as systolic blood pressure $140 mm Hg, diastolic blood pressure
$90 mm Hg, or pharmacologic treatment.
Genotyping Platforms for Genome-Wide Genotype and
Imputation
For the present study, the CARe consortium genotyped the IBC
SNP chip [15] in 23767 European Americans and 8110 African
Americans, as well as the Affymetrix 6.0 chip in 7382 African
Americans. The IBC array contains nearly 50,000 SNPs across
2,000 loci. SNPs were selected using a tagging approach among
populations represented in HapMap and the SeattleSNPs project.
The array was designed to focus on candidate loci related to
cardiovascular disease and its risk factors. More details can be
found in the design paper [15]. Table S1 details the genotyping
that was conducted. For the CARe study cohorts, quality control
and imputation were conducted centrally using MACH 1.0.16
(http://www.sph.umich.edu/csg/abecasis/MaCH/). Imputation
results were filtered using thresholds RSQ_HAT value of 0.3
and minor allele frequency 0.01. Fractional counts between 0 and
2 were coded for the imputed genotypes in order to estimate the
number of copies of a pre-specified allele. For European samples,
the CEU population from HapMap 2 (2.54 million SNPs) was
used as the reference panel.
For African American samples, a 1:1 combined HapMap 2
CEU+YRI reference panel was used. This panel includes SNPs
that were present in both populations, as well as SNPs segregating
in one panel and monomorphic and nonmissing in the other (2.74
million altogether). Since the African American samples were
genotyped for both the Affymetrix 6.0 and IBC arrays, we were
able to analyze imputation performance at non-genotyped SNPs.
The use of the CEU+YRI panel resulted in an allelic concordance
rate of ,95.6%, calculated as 1 – 1/2*|imputed_dosage –
chip_dosage| for imputation on the Affymetrix chip. This is
similar to rates obtained from African ancestry participants
imputed using HapMap 2 YRI individuals [39].
Statistical Methods for Discovery Stage
Trait creation details are described above (Renal Function
Indices). Performed centrally but within each individual study,
genome-wide association analyses and IBC chip analyses of
natural log-transformed eGFR, UACR, CKD, and MA were
conducted using linear and logistic regression with an additive
genetic model. We adjusted for age, sex and study site (when
applicable) and the first 10 principal components; relatedness was
accounted for when necessary using linear mixed effect (LME)
models for eGFR and UACR and logistic regression via
generalized estimating equations (GEE) for CKD and MA.
Additional details regarding the discovery cohorts are in Text S1.
Principal Components Analysis
Principal components were generated using EIGENSTRAT
[40] within each study using the CARe African ancestry Affy6.0
genotype data. Two reference populations were included in the
principal component analysis of African Americans: 1,178
European Americans from a multiple sclerosis GWA study (from
Dr. Phil de Jager and colleagues), and 756 Nigerians from the
Yoruba region from a hypertension GWA (provided by Dr.
Richard Cooper and colleagues). Importantly, these two under-
went extensively quality control procedures to remove population
outliers using PCA. Ten principal components were generated for
each study and used to adjust for population substructure.
Meta-Analysis
We performed fixed-effect meta-analyses of the IBC chip and
genome-wide association data using the inverse-variance weighted
approach in METAL (http://www.sph.umich.edu/csg/abecasis/
Metal/index.html). Genomic control correction was applied after
calculating the inflation factor lambda (l) within each individual
study and after the genome-wide association meta-analysis was
performed.
The standard threshold of p,5610
28 for genome-wide
significance in the genome-wide association and p,2.0610
26 in
the IBC chip analyses was used. The rationale for the p-value
threshold used for the IBC chip is based on an empiric test of the
number of independent loci (,25,000) that appear on the IBC
array [17]. We selected independent SNPs (pairwise r
2,0.2) at
each locus for replication.
The R software (v2.9.0) was used for data management,
statistical analyses and graphing.
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We developed a set of criteria to validate the lead SNPs and
interrogate regions around each of the loci that were previously
reported among European ancestry (EA) participants [3,4] in our
African American (AA) CARe samples. For each lead SNP in EA,
we looked-up the respective association result with eGFR in AA.
To accommodate the difference of LD structure and possible
allelic heterogeneity across different ethnicities, we then interro-
gated the 250 kb flanking region around each lead SNP to
determine whether there exist other SNPs with stronger
associations with the outcome. We used the following criteria to
identify the top AA SNP: 1) the SNP with the smallest association
p-value within the region; 2) MAF .0.03; 3) location of the AA
lead SNP within the same recombination block of the lead EA
SNP, where the recombination block was defined as a 20%
recombination rate. The statistical significance of each identified
SNP was evaluated using a region-specific Bonferroni correction.
We determined the number of independent SNPs based on the
variance inflation factor (VIF), which was calculated recursively
within a sliding window with size 50 SNPs and pairwise r
2 value of
0.2 using PLINK.
Finally, each identified top SNP in AA was sent for replication
in additional independent AA samples.
Interrogation of CARe Loci in CKDGen
Similar to the interrogation in AA for the EA lead loci, we also
interrogated the newly identified loci from the CARe GWAS and
the IBC chip in EA participants of the CKDGen consortium.
Stage 2 Replication Analysis
Replication analyses were performed using imputed in silico
genome-wide association data; replication studies conducted the
same association analyses as the Stage 1 phase. Details regarding
the replication cohorts can be found in Text S1.
Replication was performed as follows: meta-analysis was
conducted in the Stage 2 studies only, and then in the Stage 1 +
Stage 2 studies combined. Replication was defined as a direction-
consistent Stage 2 beta coefficient; replication p-values are thus
represented as one-sided tests. SNPs were declared to replicate
when the p-value in the Stage 1 + Stage 2 studies combined was
smaller than the p-value in the Stage 1 alone.
Cross-Trait Analyses
The correlation between ln(UACR) and ln(eGFR) can range
from non-significant to as high as 0.237 (p,0.001) in our study;
therefore, we examined the cross-trait associations across albu-
minuria and eGFR phenotypes.
Functional Studies in Zebrafish
Zebrafish were maintained in accordance with established
procedures and IACUC approval. At the one-cell stage, zebrafish
embryos were injected with varying doses of morpholino antisense
oligonucleotides (MO, GeneTools, Philomath OR). MO sequenc-
es are shown in Table S6. For in vivo observations, edema
development was documented at 5-days post-fertilization.
In situ hybridization was performed according to established
procedures (http://zfin.org/ZFIN/Methods/ThisseProtocol.html).
To visualize different regions of the kidney, we used pax2a (global
kidney marker) [41], wt1a (podocyte marker) [41], nephrin (podocyte
marker) [31], slc20a1a (proximal tubule) [42], and slc12a3 (distal
tubule marker) [42]. The morphology of the expression pattern was
independently scored by two investigators. Electron microscopy was
performed as previously described [41].
Dextran clearance was assessed as described previously [20],
48 hours after morpholino injection, embryos were manually
dechorionated, anesthetized in a 1:20 dilution of 4 mg/ml
Tricaine in egg water and positioned on their back in a 1%
agarose injection mold. An equal volume of tetramethylrhodamine
dextran (10,000 MW; Invitrogen) was injected into the cardiac
sinus venosus of each embryo, after which embryos were returned
to fresh egg water. Embryos were imaged by fluorescence
microscopy 6 hours post-injection (54 hpf) to demonstrate equal
loading, then subsequently imaged at 72 and 96 hpf to evaluate
dextran clearance. Confocal images were obtained from agarose
embedded embryos using a Zeiss LSM500 microscope.
Supporting Information
Figure S1 Quantile-quantile plots for genome-wide association
for A) eGFR; B) CKD; c) UACR; 4) MA.
(TIF)
Figure S2 Manhattan plots for genome-wide association for A)
eGFR; B) CKD; c) UACR; 4) MA.
(TIF)
Figure S3 Regional association plots for all confirmed or
replicating loci from the CKDGen loci interrogation; the blue
notation represents the best SNP in whites with the p-value in
African Americans, whereas red represents the lead SNP in
African ancestry participants; the linkage disequilibrium shown
uses YRI information from Hapmap2.
(PDF)
Figure S4 Regional association plot for the MYH9-APOL1
region in African ancestry participants.
(TIF)
Figure S5 Analysis of glomerular architecture after kcnq1
knockdown by electron microscopy does not reveal significant
changes. (a–c) Glomerular architecture at 120 hpf after injection
of control morpholino visualized by electron microscopy at 8000-,
15,000, and 50,000-fold magnification reveals endothelial capil-
laries (C) with basement membrane (BM), podocytes (P) and foot
processes (FP) similar to mammalian glomerular ultrastructure.
(d–f) Transient knockdown of kcnq1 does not significantly change
glomerular anatomy.
(TIF)
Figure S6 Dok6 and fndc1 knockdown in zebrafish embryos
does not affect kidney development. (a–e) Uninjected control
zebrafish embryos show normal glomerular and tubular morphol-
ogy, as shown by in situ hybridization for the global kidney marker
pax2a (a, inset showing lower-magnification image, with staining
in both glomerulus and tubules), the podocyte markers wt1a (b)
and nephrin (c), and the proximal and distal tubular markers
slc20a1a (d) and slc12a3 (e). (f–o) Injection of dok6 (f–j) or fndc1
(k–o) morpholinos at the one-cell stage results in no significant
changes in glomerular or tubular gene expression.
(TIF)
Figure S7 kcnq1 knockdown enhances loss of fluorescent
dextran. Control and kcnq1 MO injected embryos were loaded
with rhodamine-labeled dextran at 48 hpf. .80 embryos were
analyzed for each group in 3 separate experiments (a,d)
Fluorescence microscopy at 6 hpi reveals equal fluorescence
loading between embryos. (b,e) At 72 hpf (24 hpi), fluorescence
intensity in kcnq1 morphants is diminished. (c,f) At 96 hpf (48 hpi)
control embryos retain their fluorescence, but kcnq1 morphants
have significantly diminished fluorescence.
(TIF)
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(DOC)
Table S2 Genome-wide significant loci: SNP imputation
quality* in Discovery and Replication cohorts.
(DOC)
Table S3 Known loci for eGFRcrea and eGFRcys among
participants of European Ancestry present on the IBC chip.
(DOC)
Table S4 Cross-trait associations for novel loci from Stage
1+Stage 2 in participants of African ancestry.
(DOC)
Table S5 Diabetes and Hypertension stratified analyses, Stage 1
data.
(DOC)
Table S6 Morpholino sequences.
(DOC)
Text S1 Study-specific methods.
(DOC)
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